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Original Article
Purpose: We investigated the role of radiotherapy (RT) for pancreatobiliary neuroendocrine tumors (PB-NETs).
Materials and Methods: We identified 9 patients with PB-NETs who received RT between January 2005 and March 2012. 
Of these 9 patients, 4 were diagnosed with NETs in the pancreas and 5 were diagnosed with NETs in the gallbladder. All patients 
received RT to the primary tumor or resection bed with a median total irradiation dose of 50.4 Gy, with or without chemotherapy.
Results: The tumor response rate and tumor control rate in the RT field were 60% and 100 %, respectively. All 4 patients who 
underwent surgery had no evidence of disease in the RT field. Of the 5 patients who received RT to the primary gross tumor, 1 
had complete response, 2 had partial response, and 2 had stable disease in the RT field. The median time to progression was 11 
months. Of the 9 patients, four patients had no progression, and 5 patients had progression of disease (locoregional, 2; distant, 2; 
locoregional/distant, 1). Of the 4 patients without progression, 3 were treated with RT in adjuvant or neoadjuvant setting, and one 
received RT to primary tumor. One patient experienced radiation-induced duodenitis at 3 months after concurrent chemoradiation 
without treatment-related mortality.
Conclusion: RT can yield local control for advanced PB-NETs. RT should be considered an essential part of multimodality 
treatment in management of advanced PB-NETs.
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Introduction
Pancreatobiliary neuroendocrine tumors (PB-NETs) are uncom-
mon malignancies arising from the neuroendocrine system of 
the pancreatobiliary tract. The annual incidence is estimated 
at <5 in 1,000,000 in Asian, United States, and European 
studies [1-5]. Improvement of diagnostic tools and growing 
awareness of gastrointestinal NETs have resulted in increased 
detection, and thus, increased incidence of PB-NETs worldwide. 
Halfdanarson et al. [6] reported an annual incidence of 2.2 
in 1,000,000, covering a period of 27 years, with a higher 
incidence in PB-NETs in recent decades. In Korea, Cho et al. 
[7] reported that the incidence of gastroenteropancreatic 
neuroendocrine tumors (GEP-NETs) has shown a remarkable 
increase during the last decade and the incidence of PB-NETs 
is 9.5% of all GEP-NETs. 
  For treatment of PB-NETs, a multidisciplinary approach 
including surgical resection and chemotherapy is acceptable 
[8], but advanced PB-NETs still remain a difficult therapeutic 
challenge because of their high malignant potential and 
resistance to conventional chemotherapy with etoposide, 
platinum agents, anthracyclines, streptozocin, and 5-fluorou-
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racil (5-FU) based agents [1,9]. Thus, there is not yet a consen-
sus on appropriate therapeutic approaches in the management 
of PB-NETs. Radiotherapy (RT), or combined chemoradiation 
(CRT), has not been widely used in the management of PB-
NETs, and also has not been incorporated into multidisciplinary 
management of PB-NETs.
  In this study, we retrospectively analyzed clinical outcomes to 
investigate the potential role of RT for PB-NETs patients. This 
study provided a single institution experience of patients with 
PB-NETs who were treated with external beam radiation (EBRT) 
intended for curative purposes.
Materials and Methods
1. Patient eligibility
We included patients diagnosed with PB-NETs who were 
treated with RT with or without chemotherapy at our insti-
tution between January 2005 and March 2012. We identified 9 
patients (7 males, 2 females) who had a pathological diagnosis 
of PB-NETs and who received EBRT to the primary tumor or 
resection bed.
2. Radiotherapy technique
All patients received RT to the primary tumor or resection 
bed for a total irradiated dose of 45 Gy or above, with or 
without chemotherapy. All patients received 3-dimensional 
conformal radiotherapy with energies ≥6 MV generated by 
a linear accelerator or intensity modulated radiation the-
rapy (IMRT) by tomotherapy HI-ART II (TomoTherapy Inc., 
Madison, WI, USA). The treatment volume consisted of the 
gross tumor volume, defined by pancreatic and locoregional 
radiographic abnormalities identified by contrast-enhanced 
computed tomography (CT), the clinical target volume, defined 
as the area at risk for subclinical microscopic disease, and 
the planning target volume, typically consisting of a 0.5-cm 
margin outside of the clinical target volume. The RT technique 
consisted of multi-field techniques. If the patients received RT 
to the primary tumor, after a dose of 41.4 Gy in 23 fractions, 
the field was reduced to protect the critical organ and then an 
additional boost of 5.4 to 9.0 Gy was delivered in fractions of 
1.8 Gy.
3. Treatment outcome assessment
Patients were considered assessable if measurable disease on 
CT scan or positron emission tomography-CT was present prior 
to the initiation of treatment. Response to treatment in the RT 
field was evaluated using revised Response Evaluation Criteria 
in Solid Tumors (ver. 1.1) criteria [10], with complete response 
(CR) defined as the disappearance of the all target lesions, 
partial response (PR) defined as at least a 30% decrease in the 
sum of diameters of target lesions and progressive disease (PD) 
defined as at least a 20% increase in the sum of diameters 
of target lesions. Stable disease (SD) was defined as neither 
sufficient shrinkage to qualify for PR nor sufficient increase 
to qualify for PD. Additionally, no evidence of disease (NED) 
was defined as no objective evidence of tumor recurrence for 
patients treated with surgery. The tumor response rate for 
primary tumor was the proportion of CR and PR, and tumor 
control rate for primary tumor or resection bed was the 
proportion of NED, CR, PR, and SD. Local failure was defined 
as tumor recurrence in the primary site, regional failure was 
tumor recurrence in the regional lymph nodes, and recurrences 
at other sites were regarded as distant failure. Survival was 
defined as the time from the date of initiation of RT to the 
date of death as a result of any cause. Time to progression (TTP) 
was defined as the time from the date of initiation of RT to 
the first objective documentation of tumor progression or to 
the time of death as a result of PD in the absence of previous 
documentation of objective PD.
4. Toxicity assessment
We defined acute toxicities as events occurring within 3 
months from the start of RT. Late toxicities were defined 
as events occurring after 3 months from the start of RT. All 
toxicities were graded according to the Common Terminology 
Criteria for Adverse Events (ver. 3.0) and toxicities rated higher 
than grade 3 were considered severe. 
Results
1. Patient and treatment characteristics 
The median age at the time of initiation of treatment was 54 
years (range, 38 to 61 years). Seven patients (77.8%) were 
men. All patients had the Eastern Cooperative Oncology 
Group performance of 0 or 1. Of the 9 patients, 4 patients 
were diagnosed with NET in the pancreas and 5 patients were 
diagnosed with NET in the gallbladder. Prior to treatment, 7 
patients had locally advanced NET, 1 patient had adjacent liver 
metastasis, and 1 patient had para-aortic lymph node and 
adjacent liver metastasis. Six patients were diagnosed with 
poorly differentiated NETs. Among 9 patients, 4 underwent 
surgical resection. One patient was treated with preoperative 
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RT followed by surgery and 3 patients were treated with 
surgery followed by postoperative RT. All four patients who 
underwent surgical resection had tumor resection with 
negative margins. 
  The median of the total irradiation dose was 50.4 Gy (range, 
45.0 to 58.4 Gy). All patients completed the full course of RT 
with or without chemotherapy at the intended dose with out 
dose reduction. Six patients received EBRT by a linear accele-
rator from 45.0 to 50.4 Gy at 1.8 Gy daily, 5 times a week, 
and 3 patients were treated with IMRT by tomotherapy from 
55.7 to 58.4 Gy at 2.2 to 2.9 Gy daily, 5 times a week. Of the 
9 patients, 7 received a combination of concurrent CRT, and 
2 patients received RT alone. Four patients were treated with 
etoposide plus carboplatin, 2 patients were treated with 5-FU, 
and 1 patient was treated with etoposide, and carboplatin 
plus 5-FU with concurrent RT. Five patients were treated with 
CRT to primary tumor, and 4 patients underwent resection 
with adjuvant CRT/RT or neoadjuvant CRT. The patient and 
treatment characteristics are summarized in Table 1.
2. Treatment outcome 
Of the 9 patients, four patients (45%) underwent surgery with 
NED in the RT field, despite absence of additional treatment. 
Of the remaining 5 patients, three patients (33%) who received 
concurrent CRT were diagnosed with locally advanced PB-NETs 
with or without distant metastasis and experienced CR or PR 
in the RT field. Fig. 1 illustrates the regression in tumor size of 
patient #5. Two (22%) of the 5 patients demonstrated SD in 
the RT field. The tumor response rate for primary tumor and 
tumor control rate for primary tumor or resection bed were 
60% (20% CR, 40% PR, and 40% SD) and 100% (45% NED, 
11% CR, 22% PR, and 22% SD), respectively.
  The median follow-up period for surviving patients was 16 
months (range, 13 to 59 months) and the median TTP was 
11 months (range, 2 to 59 months). Four patients were alive 
without progression, 1 patient was alive with progression, 
and 4 patients were dead with progression. Progression of 
disease occurred in 5 patients with 2 locoregional failures, 2 
distant failures, and 1 synchronous locoregional and distant 
failure. Three of 4 patients underwent surgery and one of 
5 patients who received concurrent CRT were alive without 
disease. One patient (patient #6) who survived 5 years from 
preoperative concurrent CRT followed by surgery without 
tumor recurrence was diagnosed initially with locally advanced 
well differentiated NET without lymph node metastasis in the 
pancreas. The prominent pattern of mortality in patients was Ta
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not locoregional failure, but distant metastasis. The treatment 
outcomes with survival status are shown in Table 2.
3. Toxicity
The three patients experienced acute hematologic toxicities 
above grade 3. Two patients had grade 3 neutropenia and 1 
had grade 3 thrombocytopenia during concurrent CRT. No 
acute non-hematologic grade 3 and 4 toxicities were observed. 
Late toxicity was observed in one patient who experienced 
grade 3 radiation-induced duodenitis at 3 months after 
Fig. 1. Abdominal computed tomography scans of 51-year-old male patient diagnosed as having gallbladder neuroendocrine tumor 
with lymph node involvement and adjacent liver metastasis (arrow) treated with radiotherapy (RT) to gross mass: (A) 1 month before RT, 
(B) 1 month after RT, and (C) 12 months after RT.
Table 2. Treatment outcomes of radiotherapy for pancreatobiliary neuroendocrine tumors
No.
Infield 
outcome
Recurrence
TTP 
(mo)
Remark
Last 
follow-up 
status
OS 
(mo)
1
2
3
4
5
6
7
8
9
SD
SD
PR
PR
CR
NED
NED
NED
NED
DM
R
L + R + DM
DM
No 
No 
No 
R
No 
2
11
5
3
-
-
-
5
-
SD of primary tumor and LN site, but developed liver and lung metastasis
SD for 11 months, and then regional LN progression
PR for 5 months, and then primary tumor, LN and liver progression
PRof primary tumor site, but progressive liver metastasis
(CR at 12 mo)
(NED for 5 yr)
(NED for 16 mo)
NED for 4 mo, and then regional LN recurrence
(NED for 15 mo)
DWD
AWD
DWD
DWD
NED
NED
NED
DWD
NED
28
15
8
2
12
60
16
12
15
TTP, time to progression; OS, overall survival; SD, stable disease; DM, distant metastasis; LN, lymph node; CR, complete response; PR, 
partial remission; PD, progressive disease; NED, no evidence of disease; L, local recurrence; R, regional recurrence; DWD, died with dis-
ease; AWD, alive with disease.
Table 3. Overview of published results 
Author
No. of 
patients 
Treatment modality Remark
Strosberg et al. [11]
Torrisi et al. [12]
Rich [13]
Saif et al. [14]
Zagar et al. [15]
Present
6
3
3
6
17
9
CCRT
RT
RT
CCRT or sequential CRT
CCRT
CCRT or RT
Tumor response rate 80% 
One patient: PR for 4 yr, another: PR for 7 mo
One patient: resolved local symptoms for 39 mo
Tumor response rate 100%; one patient: alive for 9 yr, another: alive for 4.5 yr
Local control rate 85%; 2-yr distant metastatic-free survival 46%
Tumor response rate 60%; tumor control rate 100%; median TTP 11 mo; one 
patient: alive for 5 yr
CCRT, concurrent chemoradiation; RT, radiotherapy; CRT, chemoradiation; TTP, time to progression.
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concurrent CRT. There were no treatment-related deaths.
Discussion and Conclusion
RT has not historically played a major role in the treatment of 
PB-NETs. This study included a series of patients with PB-NETs 
treated with curative-intent RT for primary gross disease, or 
after resection. Our findings show that RT could be an optional 
treatment modality for achieving local control in management 
of PB-NETs. RT produced excellent tumor control rate and 
yielded local control in patients with advanced PB-NETs. In 
terms of toxicity associated with this treatment, 3 patients 
had acute hematologic grade 3 toxicities and 1 patient had 
late gastrointestinal grade 3 toxicities. However, there were no 
treatment-related deaths. 
  A review of the literature showed that the role of RT in the 
management for PB-NETs had not been extensively evaluated 
because of the low incidence of this tumor. Few reports have 
described RT use for PB-NETs. Strosberg et al. [11] reported a 
study in which 6 patients were treated with a combination 
of concurrent and sequential CRT for treatment of locally 
advanced pancreatic NETs. The radiologic response rate was 
80% of patients and all patients tolerated the CRT. Torrisi et al. 
[12] reported 2 patients with locally advanced pancreatic NETs, 
1 of whom was treated with a combination of intraoperative 
iodine-125 brachytherapy followed by 41.4 Gy EBRT, and the 
other patient was treated with a combination of EBRT to a 
dose of 45 Gy and chemotherapy. The first patient achieved 
a prolonged PR of over 4 years, whereas the second patient 
achieved a PR lasting 7 months and then had recurrence. 
Rich [13] described a patient with pancreatic NET who 
received 46.5 Gy EBRT and had resolved local symptoms for 
39 months until the local tumor recurred. The patient died 
61 months from the start of irradiation, despite subsequent 
chemotherapy consisting of 5-FU and streptozocin. Recently, 
Saif et al. [14] reported that all 6 patients with pancreatic NET 
treated with concurrent CRT consisting of capecitabine or 
5-FU experienced clinical benefit and PR. One patient survived 
9 years from treatment and another patient was alive at 4.5 
years. These studies documenting clinical outcomes from RT 
in patients with PB-NETs have suggested that PB-NETs are not 
radioresistant, but are radioresponsive [11-15]. 
  In our series, both locoregional failure and distant failure 
in patients receiving CRT/RT in adjuvant or neoadjuvant 
setting were higher than those who received CRT/RT to 
primary gross disease. In the adjuvant or neoadjuvant setting, 
patients of PB-NETs treated with curative-intent RT had 25% 
locoregional failure and no distant failure. And patients who 
received concurrent CRT to the primary gross tumor had 40% 
locoregional failure and 60% distant failure. Zagar et al. [15] 
from the Duke University reviewed the 33 resected pancreatic 
NETs patients treated with or without RT in the adjuvant or 
neoadjuvant setting. Of the 33 patients, sixteen patients were 
treated with surgical resection alone, while 17 underwent 
resection with adjuvant or neoadjuvant RT. The 2-year local 
control rate was 85% for surgery with RT group and 90% for 
the surgery alone group (p = 0.38). The authors concluded 
that the role of RT in the adjuvant management of pancreatic 
NETs remains unclear. However, no statistically significant 
difference of local control seen between both groups could be 
explained by factor that the potential probability of surgery 
with RT group had more patients with an aggressive tumor 
biology/more locally aggressive disease patients compared 
with the surgery group. Solorzano et al. [16] reported that, of 
patients with pancreatic NETs who undergo surgical resection 
with curative intent, 50% will develop a recurrence within 5 
years. In present study, the finding that RT in the adjuvant 
setting had a 75% locoregional control rate without distant 
recurrence is useful information in the treatment of this 
disease. A summary of published studies with PB-NETs patients 
treated with RT are shown in Table 3.
  There have been several studies that used a targeted peptide 
receptor analog in the management of advanced or metastatic 
NETs to improve clinical responses. Kwekkeboom et al. [17] 
reported the GEP-NETs showed high response rates to the 
somatostatin analog octreotate. The recent success of the 
biologic targeted agents, such as everolimus, sunitinib and 
endostatin, has renewed excitement about treating advanced 
pancreatic NETs [18-20]. Biologic targeted agents have anti-
angiogenic properties, whereas RT is known to block the 
growth of tumor vasculature. So, the combination of targeted 
agents and EBRT might be an effective treatment for this 
disease based on the rationale that PB-NETs are highly vascular 
tumors.
  Our study was limited because the analysis was retrospective 
and the number of patients was small, but there are very few 
studies on the treatment outcome of RT for PB-NETs because 
of the low incidence of this tumor and the low therapeutic 
application of RT for this disease. For all those reasons, 
prognostic parameter related progression and survival were 
unable to analysis in this study. 
  In conclusion, our experience provide that RT with or without 
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chemotherapy can be used as an effective treatment modality 
in the management of advanced PB-NETs. RT may induce 
tumor response/control and achieve local control of PB-NETs. 
The future role of RT in combination with chemotherapy or 
biologic modifiers for the treatment of PB-NETs remains to be 
established. We suggest that RT should be considered as a part 
of multimodality therapy in curative management of advanced 
PB-NETs.
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